Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 5/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.53 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.45 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ddctp SCHEMBL30586989 | 1.00 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL20879464 | 1.00 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL16807754 | 1.00 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| Ddctp SCHEMBL18840498 | 1.00 | POLG (0.70) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL543438 | 0.98 | POLG (0.67) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL543055 | 0.92 | POLG (0.60) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL543054 | 0.92 | POLG (0.60) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL1763274 | 0.91 | POLG (0.59) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL23157013 | 0.90 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 | |
| SCHEMBL21895844 | 0.90 | POLG (0.55) | POLGPOLBP2RY2P2RY4P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1949 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095103-A | Mutant DNA polymerase and methods of use thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-12630865-B2 | Products and processes for multiplex nucleic acid identification | AGENA BIOSCIENCE, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4724455-A1 | MULTIVALENT BINDING UNIT MODIFIED DIDEOXYNUCLEOTIDE TRIPHOSPHATES AND METHODS OF MAKING AND USING THE SAME | ILLUMINA, INC. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12597490-B2 | Methods and systems for modeling phasing effects in sequencing using termination chemistry | Life Technologies Corporation (US) | 2026-04-07 | — | — | US | claimed |
| WO-2025235939-A1 | METHODS FOR BALANCED AMPLIFICATION OF SMALL SAMPLES OF NUCLEIC ACIDS | ORCHID BIOSCIENCE, INC. (US) | 2025-11-13 | — | — | WO | claimed |
| US-12454722-B2 | Multiplexed method for the identification and quantitation of minor alleles and polymorphisms | AGENA BIOSCIENCE, INC. (US) | 2025-10-28 | — | — | US | claimed |
| EP-4605547-A1 | NOISE REDUCTION FOR DATA STORAGE IN DNA | Catalog Technologies, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| WO-2025105897-A1 | METHOD FOR DETECTING GENOMIC MUTATION THROUGH NUCLEIC ACID PATTERN-BASED PURIFICATION, AND DISEASE DIAGNOSIS METHOD USING SAME | 광주과학기술원 | 2025-05-22 | — | — | WO | claimed |
| US-20250154557-A1 | COMPOSITION FOR SELECTING NUCLEIC ACIDS OF INTEREST, AND A METHOD FOR SELECTING NUCLEIC ACIDS USING THEREOF | GWANGJU INST SCIENCE & TECH (KR) | 2025-05-15 | — | — | US | claimed |
| WO-2025042729-A1 | CELL PREPARATION COMPOSITION, SYSTEM AND METHOD FOR SINGLE CELL TRANSCRIPTOMICS | Life Technologies Corporation (US) | 2025-02-27 | — | — | WO | claimed |
| EP-0496749-A4 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | — | 1993-06-16 | — | — | EP | claimed |
| WO-1992022306-A1 | TRANSFORMED ERYTHROCYTES, PROCESS FOR PREPARING THE SAME, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-23 | — | — | WO | claimed |
| EP-0496749-A1 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION. | APPLIED BIOSYSTEMS (US) | 1992-08-05 | — | — | EP | claimed |
| EP-0286418-B1 | ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEMS FOR THE SAME | US COMMERCE (US) | 1992-07-08 | — | — | EP | claimed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | claimed |
| WO-1991005060-A2 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS, INC. (US) | 1991-04-18 | — | — | WO | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| US-4879277-A | 2',3'-DIDEOXYCYTIDINE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1989-11-07 | — | — | US | claimed |
| EP-0298280-A2 | Animal derived cell with antigenic protein introduced therein | HAPGOOD, C.V., a Netherlands Antilles Limited Partnership (US) | 1989-01-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630865-B2 | Products and processes for multiplex nucleic acid identification | POLM, POLN, POLL | POLG 128/4885POLB 6/4885P2RY2 2279/4885 |
| US-12597490-B2 | Methods and systems for modeling phasing effects in sequencing using termination chemistry | RNGTT, TRHR, RIF1 | POLG 140/4885POLB 13/4885P2RY2 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.